Skip Navigation


European Heart Journal Advance Access originally published online on November 4, 2005
European Heart Journal 2006 27(2):121-122; doi:10.1093/eurheartj/ehi639
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/2/121    most recent
ehi639v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Agewall, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agewall, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Matrix metalloproteinases and cardiovascular disease

Stefan Agewall*

Department of Cardiology, Karolinska Institute, Karolinska University Hospital, S 141 86 Stockholm, Sweden

* Corresponding author. Tel: +46 8 585 800; fax: +46 8 585 867 10. E-mail address: stefan.agewall@karolinska.se

This editorial refers to ‘Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study’{dagger} by E. Lubos et al., on page 150

The first 10% of the full text of this article appears below.

Introduction

Matrix metalloproteinases (MMPs) are a group of endopeptidases with capacity to cleave components of extracellular matrix, such as collagen and elastin.1 The ability to modify the tissues is important for several aspects of normal and abnormal physiology. Approximately 20 different MMPs are identified, and they can be subdivided into different groups according to which components of the extracellular matrix they degrade. MMPs are secreted in a latent proform and require activation for proteolytic activity. The activity of MMPs is normally low in healthy tissue, but the increased expression and activity of several MMPs in a . . . [Full Text of this Article]

Mechanisms

Clinical studies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study
Edith Lubos, Renate Schnabel, Hans J. Rupprecht, Christoph Bickel, Claudia M. Messow, Susanne Prigge, François Cambien, Laurence Tiret, Thomas Münzel, and Stefan Blankenberg
EHJ 2006 27: 150-156. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
S. Ayalasomayajula, C.-M. Yeh, S. Vaidyanathan, B. Flannery, H. A. Dieterich, D. Howard, M. P. Bedigian, and W. P. Dole
Effects of Aliskiren, a Direct Renin Inhibitor, on Cardiac Repolarization and Conduction in Healthy Subjects
J. Clin. Pharmacol., July 1, 2008; 48(7): 799 - 811.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
A. H. Gradman and R. Kad
Renin inhibition in hypertension.
J. Am. Coll. Cardiol., February 5, 2008; 51(5): 519 - 528.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. J. Bax, B. De Bruyne, A. K. Gitt, S. Kristensen, C. Linde, D. Poldermans, F. J. Pinto, P. Ponikowski, B. D. Prendergast, E. Abagiti-Rosei, et al.
Highlights of the 2006 Scientific Sessions of the European Society of Cardiology: Barcelona, Spain, September 2-5, 2006
J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2564 - 2574.
[Full Text] [PDF]